Skip to main content

Acumen Pharmaceuticals, Inc 8-K, filed Oct 30, 2026

Acumen Pharmaceuticals, Inc. (ABOS)

8-K 2026-10-30 For: 2026-10-30
View Original
Added on October 30, 2026

About this 8-K

Acumen Pharmaceuticals, Inc filed this 8-K on October 30, 2026.

Acumen Pharmaceuticals, Inc. said Phase 2 ALTITUDE-AD missed its primary endpoint at 18 months for both 35 mg/kg and 50 mg/kg doses, plans to cease sabirnetug development, implement cash conservation measures and explore strategic options. AI summary

Items reported

  • Item 7.01: Regulation FD disclosure
  • Item 8.01: Other events
  • Item 9.01: Financial statements and exhibits